Check-Cap (NASDAQ:CHEK) downgraded to Hold at Zacks Investment Research


Zacks Investment Research downgraded shares of Check-Cap (NASDAQ:CHEK – Get an Assessment) from a buy rating to a hold rating in a report released Thursday morning, Zacks.com reports.

According to Zacks, “Check Cap Ltd. is a medical diagnostic company. The Company is engaged in the development of an ingestible imaging capsule for colorectal cancer screening. Check Cap Ltd. is based in Mount Carmel, Israel. “

Separately, Dawson James upgraded Check-Cap shares from a neutral to a buy rating in a Monday, Feb. 7 research note.

Check-Cap shares opened at $0.37 on Thursday. The stock has a market capitalization of $36.14 million, a price-earnings ratio of -1.78 and a beta of 0.20. The company has a 50-day moving average of $0.41 and a 200-day moving average of $0.63. Check-Cap has a 12-month low of $0.34 and a 12-month high of $1.91.

Check-Cap (NASDAQ:CHEK – Get Rating) last released its quarterly earnings data on Thursday, April 7. The medical research company reported ($0.06) EPS for the quarter. Equity research analysts expect Check-Cap to post year-to-date EPS of -0.17.

Hedge funds have recently increased or reduced their holdings in the stock. Goldman Sachs Group Inc. increased its stake in Check-Cap by 242.5% in the fourth quarter. Goldman Sachs Group Inc. now owns 305,991 shares of the medical research company worth $206,000 after acquiring an additional 216,662 shares in the last quarter. Millennium Management LLC acquired a new equity stake in Check-Cap in Q4 valued at $44,000. GSA Capital Partners LLP purchased a new equity stake in Check-Cap during Q4 for $206,000. ARK Investment Management LLC increased its stake in shares of Check-Cap by 6.8% during the fourth quarter. ARK Investment Management LLC now owns 3,257,788 shares of the medical research company worth $2,198,000 after purchasing an additional 207,260 shares last quarter. Finally, Two Sigma Securities LLC bought a new position in Check-Cap in the third quarter worth $44,000. Hedge funds and other institutional investors hold 4.67% of the company’s shares.

Check Cap Company Profile (Get a rating)

Check-Cap Ltd., a clinical-stage medical diagnostics company, is engaged in the development of capsule-based screening technology that uses ultra-low dose x-rays to scan the inner lining of the colon at the search for precancerous polyps and other structural abnormalities in Israel. Its C-Scan system consists of C-Scan Cap, an X-ray scanning capsule for the detection of suspicious polyps; C-Scan Track, a disposable system attached to the patient’s back by biocompatible adhesive skin patches; and C-Scan View software, a client/server application that allows downloading of procedure data from the C-Scan Track, data analysis and report generation.

Featured articles

Get a Free Copy of Zacks Research Report on Check-Cap (CHEK)

For more information on Zacks Investment Research’s research offerings, visit Zacks.com



Get news and reviews for Check-Cap Daily – Enter your email address below to receive a concise daily summary of breaking news and analyst ratings for Check-Cap and related companies with MarketBeat.com’s free daily email newsletter.